Ziekenhuis Rivierenland
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Ziekenhuis Rivierenland, research in cardiovascular diseases focuses on improving prevention and treatment for people with atherosclerotic cardiovascular disease, atrial fibrillation, and broader cardiovascular disease risk. The trials are mainly designed to test new therapies, reduce major heart-related events, and better control rhythm problems.
- Preventing heart attack, stroke, and cardiovascular death in people at elevated risk
- Studying treatments that lower LDL cholesterol and lipoprotein(a) to reduce vascular complications
- Evaluating new options for atrial fibrillation burden and rhythm control
- Assessing therapies that may protect both heart and kidney outcomes in people with obesity
This area reflects a strong focus on long-term cardiovascular risk reduction and better outcomes for patients with established or high-risk heart and blood vessel disease.
Neoplasms
The oncology studies at Ziekenhuis Rivierenland cover several cancers, including breast cancer, multiple myeloma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and esophagogastric cancer. These trials aim to refine treatment strategies, improve disease control, and explore ways to match therapy more closely to patient response.
- Testing treatment approaches for HER2-positive breast cancer and hormone receptor-positive metastatic breast cancer
- Studying treatment duration and response-guided care in multiple myeloma and CLL/SLL
- Evaluating first-line options for esophagogastric cancer
- Exploring whether de-escalated or personalized cancer treatment can maintain effectiveness while reducing burden
Overall, this cancer research is centered on improving effectiveness and tailoring therapy to the needs of each disease type.
Eye Diseases
Research in eye diseases at this site includes studies in myopia, with a particular interest in slowing progression in children. The goal is to compare treatment options that may better preserve vision and support safe, practical long-term care.
- Studying ways to slow progressive myopia in European children
- Comparing different low-dose atropine approaches for vision care
- Assessing safety, adherence, and reasons why some patients may not respond as expected
This work reflects a pediatric eye-care focus on helping manage near-sightedness before it worsens further.
Nutritional and Metabolic Diseases
The nutritional and metabolic diseases portfolio at Ziekenhuis Rivierenland is strongly linked to obesity and overweight, often in combination with cardiovascular risk. These studies are designed to evaluate new treatments that may support weight management while also improving heart and metabolic outcomes.
- Testing therapies for people living with obesity or overweight
- Studying patients with combined atherosclerotic cardiovascular disease and excess weight
- Evaluating whether new medicines can lower the risk of major cardiovascular events
- Exploring treatments that may also support kidney protection in high-risk patients
This area shows a clear emphasis on the link between metabolic health and long-term cardiovascular prevention.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 43 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ziekenhuis Rivierenland
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 43 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Venetoclax | 3 | Unknown | 2021-02-11 | 2025-06-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.